Cidara advances CD388 to transform flu prevention strategies

Cidara Therapeutics is advancing its drug-FC conjugate, CD388, which aims to improve flu prevention. This development utilizes the company's Cloudbreak technology platform, designed to inhibit the growth of flu viruses. The new approach could significantly change how flu prophylaxis is managed, differing from traditional methods. CD388's unique mechanism may offer enhanced protection against influenza. Cidara's progress marks a notable shift in flu treatment strategies, potentially leading to more effective options for patients.